Healthcare / Drug Manufacturers - Specialty & GenericBSE
$4.33
+0.20 (+4.84%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $8.7M · quality 60.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
38/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
12/100
SEC 0%
Sin guardar todavía.
Market Cap
$103M
P/E
N/A
•EV/EBITDA
N/A
•ROE
3.7%
↑Gross Margin
N/A
•Debt/Equity
-1.05
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2024 · 2 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
-95.3%
FCF margin
—
FCF / Net income
-0.04x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-49.3M · FCF $2.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income Statement | ||||
| Net Income | $-49.3M | $-49.3M | $-55.5M | $-152.3M |
| EBITDA | $-8.6M | $-8.6M | $-14.8M | $-104.9M |
| EPS | -2.07 | -2.07 | -2.33 | -6.39 |
| Balance Sheet | ||||
| Debt/Equity | -1.05 | -1.05 | -1.09 | -1.15 |
| Cash Flow | ||||
| Free Cash Flow | $2.0M | $2.0M | $8.7M | $937.6M |
| Returns | ||||
| ROE | 3.7% | 3.7% | 4.3% | 12.4% |
| Growth & Yield | ||||
| EPS Growth | 11.2% | 11.2% | 63.5% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+59.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.33 → -2.07
Residual
+59.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.